Stock of the Week <style type="text/css">.ReadMsgBody { width: 100%; background-color: #E6F0FA; } .ExternalClass { width: 100%; background-color: #E6F0FA; } .ExternalClass, .ExternalClass p, .ExternalClass span, .ExternalClass font, .ExternalClass td, .ExternalClass div { line-height: 100%; } body { margin: 0; padding: 0; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; } div, p, a, li, td { -webkit-text-size-adjust: none; -ms-text-size-adjust: none; } table td { -webkit-text-size-adjust: none; border-spacing: 0; border-collapse: collapse; border:0 none; mso-table-lspace: 0pt; mso-table-rspace: 0pt; } a[href^="https"] { text-decoration: none; } /* Constrain email width for small screens */ @media screen and (max-width: 650px) { table[class="container"] { width: 96%!important; -moz-box-sizing:border-box; -webkit-box-sizing:border-box; box-sizing:border-box; margin:0 auto; } } /* Styles for forcing columns to rows */ @media only screen and (max-width : 650px) { /* force container columns to (horizontal) blocks */ td[class="force-col"] { display: block; text-align: left; width: auto!important; } img[class="fullwidth-img"] { width: 100%!important; } /* Make telephone numbers pretty */ a[href~="tel"] { color:#d35400!important; } /* OFFERS TABLE LAYOUT */ td[class="offers-table-header-force-col"] { border-bottom:none!important; display: block; text-align: left; width: auto!important; } td[class="offers-table-force-col"] { display: block; text-align: left; width: auto!important; padding:0 10px 10px!important; } /* TEXT WITH IMAGE LAYOUT */ td[class="textimg-img-col"] { border-bottom:none!important; display: block; text-align: left; width: auto!important; padding:10px 10px 0!important } td[class="textimg-text"] { border-bottom:none!important; display: block; text-align: left; width: auto!important; } /* 3 COL LAYOUTS */ table[class="col-3"] { border-bottom:1px solid #535353; margin-bottom:12px; } table[id="last-col-3"] { border-bottom:none; margin-bottom:0; } img[class="col-3-img"] { float: right; margin-left: 6px; max-width: 130px; } }</style>

One Big Pick. Once a Week.

SXTP WAS OUR MOST VIRAL PLAY OF 2025, DELIVERING 145+% GAINS TO MEMBERS! AND NOW IT'S BACK ON URGENT TRIANGLE BREAKOUT WATCH!

logo
60 DEGREES PHARMACEUTICALS INC.

US NASDAQ SYMBOL: SXTP
Last Price: 2.22 | Website | Latest News

Disseminated on behalf of 60 Degrees Pharmaceuticals Inc

Tonight we present a situation where we are looking for lightning to strike twice.

And by lightning, we mean TRIPLE-DIGIT GAINS with a past-winning Pharmaceutical play doing BIG things to combat malaria and seeing MASSIVE Revenue Growth...

WE ARE ISSUING AN IMMEDIATE ALERT ON SXTP!

The last time we covered SXTP just over a year ago, it delivered up to 145% GAINS in just 2 DAYS!

And now it's back, lighting up technical scanners with a potentially epic Triangle BREAKOUT Pattern and multiple indicators screaming "BULL RUN" like our RSI Momentum Indicator and MACD Cross! See below..

chart

With 52 Week Highs $17.68 - over 700% from the current price + a history of big moves, we wouldn't be surprised to see SXTP crush the upper levels of this Triangle formation.

Not to mention, the highly respected analysts at Zacks Equity Research just UPGRADED SXTP to a BUY RATING!

Fintel has a Price Target of $17.95!!!

WHY SXTP?
SXTP (60 Degrees Pharmaceuticals, Inc.), founded in 2010 and headquartered in Washington DC, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people.

SXTP achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018.

Arakoda is the only prophylactic therapy to provide protection against all stages of malaria, recommended for travelers by CDC, has convenient weekly dosing, and has an established safety profile.

So it should come as no surprise that SXTP is absolutely CRUSHING Revenue expectations with 350% GROWTH since 2022!

SINCE WE LAST COVERED SXTP...
With Revenues spiking over a cool Mil in the last year, it should come as no surprise that SXTP has been busy...

In February, the company expanded access to Arakoda by partnering with GoodRX.

In March, they announced all patients were CURED of Babesiosis, a tick-born disease that infect red blood cells, in clinical trials!

THE BOTTOM LINE
Just like last year at THIS VERY TIME - SXTP looks primed to run!

Last April gave members EASY 145% GAINS. What does this April have in store?

NASDAQ Stocks do NOT run 100%+ often!! BUT - you were in the know as a part of this newsletter last year!

It's not often you find a hidden gem with SOARING year-over-year Revenue Growth trading at these levels with this much upside!

With a Triangle Breakout Chart, Tech Indicators lighting up, Multiple BUY Ratings, and over 700% UPSIDE --- SXTP has it all and must NOT be ignored!

Make sure you put SXTP back on your screen TOMORROW MORNING and Follow on Twitter for Updates + Play-by-Play!

Good Trading,

Editor
StockoftheWeek.net

Still need an Online Broker to place trades?

Do NOT use RobinHood! Our Team HIGHLY recommends ETRADE .

Website | Unsubscribe | View in Browser

We encourage all to read the SEC's INVESTOR ALERT before reading this Newsletter.

COMPENSATION: Stockoftheweek.net has been compensated thirty thousand dollars cash via bank wire by 60 Degrees Pharmaceuticals Inc for this marketing services contract. Stockoftheweek.net does not own any shares of SXTP. Stockoftheweek.net has been previously compensated fifty thousand dollars cash via bank wire by 60 Degrees Pharmaceuticals Inc for marketing services which have expired. Stockoftheweek.net does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.

Disclaimer2